- Risk-free clinical trials marketplace for patient recruitment SubjectWell announced it raised $10 million in Series A funding led by Windham Venture Partners
SubjectWell — the risk-free clinical trials marketplace for patient recruitment — announced it raised $10 million in Series A funding led by Windham Venture Partners. Healthy Ventures and Geekdom Fund also participated in this round.
This round of funding will bolster SubjectWell’s mission of building awareness of and increasing participation in clinical research. This is done by providing a single marketplace that allows prospective patients to match to any available clinical trials.
“The largest barrier to participation in clinical trials is awareness — patients aren’t aware clinical trials exist and don’t know how to get started,” said SubjectWell CEO Ivor Clarke. “By building awareness and creating the first true trial marketplace, we provide patients with greater choice and access to innovative treatments. Our investors’ support allows us to reach more interested patients and fill our clients’ studies faster.”
“Our growth is not just deepening the patient pool,” added SubjectWell vice president of business development Tony Averbeck. “Our performance-based pricing model, where we’re only compensated for patients who randomize, is specifically designed to allow every sponsor to bring all of their trials into SubjectWell’s marketplace.”
And this round of funding will support SubjectWell’s international expansion by helping the company extend its services beyond North America and into Europe, South America, and the United Kingdom.
“Despite all the recent advances in medicine, clinical trials continue to be a major pain point for stakeholders. The vast majority of trials are delayed and many ultimately fail due to poor patient selection,” explained Windham general partner and CEO Adam Fine. “We have looked deeply at the clinical trial space and concluded that SubjectWell, with hundreds of studies already recruiting through its marketplace, has demonstrated the most effective model for enrolling clinical trials. We are excited to partner with this terrific team.”